Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

@article{Kantoff2010SipuleucelTIF,
  title={Sipuleucel-T immunotherapy for castration-resistant prostate cancer.},
  author={P. Kantoff and C. Higano and N. Shore and E. Berger and E. Small and D. Penson and C. Redfern and A. Ferrari and R. Dreicer and R. Sims and Yi Xu and M. Frohlich and P. Schellhammer},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 5},
  pages={
          411-22
        }
}
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. METHODS In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was… Expand

Paper Mentions

Interventional Clinical Trial
This is a nonrandomized, open-label trial of avelumab in subjects with metastatic castration-resistant prostate cancer (mCRPC) experiencing PSA or radiographic progression while… Expand
ConditionsMetastatic Castration-resistant Prostate Cancer
InterventionDrug
Interventional Clinical Trial
This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or… Expand
ConditionsProstate Cancer
InterventionDrug
Interventional Clinical Trial
This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in… Expand
ConditionsMetastatic Castration-resistant Prostate Cancer
InterventionDevice, Drug, Radiation
Interventional Clinical Trial
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a… Expand
ConditionsNon-Small Cell Lung Cancer
InterventionDrug
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  • C. Nabhan
  • Medicine
  • The New England journal of medicine
  • 2010
TLDR
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and there was a relative reduction in the risk of death as compared with the placebo group. Expand
Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
  • 2012
Studies have shown age to be prognostic in castration-resistant prostate cancer (2,3). Most studies investigating prognostic factors in castration-resistant prostate cancer have focused onExpand
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced
TLDR
Although no difference in time to progression was observed, a survival advantage was achieved, with a statistically meaningful 4.1-month improvement in median survival in the active arm with respect to the placebo arm. Expand
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
TLDR
The use of sipuleucel-T prolonged the overall survival among men with mCRPC and the safety profile was acceptable. Expand
Sipuleucel-T
TLDR
Almost all patients treated with sipuleucel-T in clinical trials reported an adverse event, although these were mild or moderate in severity (grade 1 or 2) in most patients. Expand
Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer
TLDR
The survival benefit, adverse event profile, and short course of treatment (4 weeks) associated with sipuleucel-T therapy make it an appealing treatment option for asymptomatic metastatic castrate resistant prostate cancer patients. Expand
Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested fromExpand
Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
TLDR
The finding of increased PSADT in the sipuleucel-T arm is consistent with its biologic activity in androgen-dependent prostate cancer (ADPC), and long-term follow-up will be necessary to determine if clinically important events, such as distant failure, are affected by therapy. Expand
Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
TLDR
Sipuleucel-T immunotherapy treatment at the current price with 96.5% certainty is not cost-effective and the specific group of patients who will benefit more from the treatment should be revealed and treated, or the cost of the vaccine should be lowered significantly to increase its economic value. Expand
Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.
  • T. Botrel, O. Clark, +4 authors R. Reis
  • Medicine
  • International braz j urol : official journal of the Brazilian Society of Urology
  • 2012
TLDR
Sipuleucel-T prolongs overall survival in patients with asymptomatic or minimally symptomatic metastatic metastatic castration-refractory prostate cancer (mCRPC). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 133 REFERENCES
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
TLDR
It is suggested that sipuleucel-T may provide a survival advantage to asymptomatic HRPC patients in a phase III study and was well tolerated. Expand
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
  • E. Small, P. Fratesi, +4 authors F. Valone
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Provenge is a novel immunotherapy agent that is safe and breaks tolerance to the tissue antigen PAP and preliminary evidence for clinical efficacy warrants further exploration. Expand
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
TLDR
The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer. Expand
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
TLDR
Oral satraplatin delayed progression of disease and pain in patients with metastatic CRPC experiencing progression after initial chemotherapy but did not provide a significant OS benefit. Expand
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
  • P. Kantoff, T. Schuetz, +11 authors W. Godfrey
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC, providing preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study. Expand
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.
TLDR
Goserelin is well tolerated and as effective as orchiectomy in patients with Stage D2 prostate cancer in a randomized, open, multicenter study conducted in 283 patients. Expand
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
TLDR
The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer. Expand
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
TLDR
M+H generated more frequent responses and a delay in both time to treatment failure and disease progression compared with hydrocortisone alone, and there was an indication that QOL was better with M+H, in particular with respect to pain control. Expand
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
TLDR
Among patients 65 years or older treated with external beam radiation therapy, brachytherapy, or cryotherapy, ADT use was associated with a higher cumulative incidence of death from cardiovascular causes, but the difference did not reach statistical significance. Expand
...
1
2
3
4
5
...